Dr. Matthew Freiberg is an internal medicine physician and cardiovascular epidemiologist. He relocated with his family to Nashville in June of 2014, and joined Vanderbilt as an Associate Professor of Medicine in the Division of Cardiovascular Medicine, Director of the Vanderbilt Center for Clinical Cardiovascular Outcomes REsearch and Trials Evaluation (V-CREATE), and the Dorothy and Laurence Grossman Chair in Cardiology. Originally from the Pacific Northwest, Dr. Freiberg received his BS from the University of Washington and completed medical school at Oregon Health Sciences University. He completed postgraduate training as a resident at University of Chicago Hospitals and fellowships at Boston University and with the Framingham Heart Study. His research interests include the impact of HIV, inflammation, altered immunity, and alcohol use on cardiovascular outcomes. He is also an expert in utilizing big data for clinical research initiatives. Dr. Freiberg has been a Veterans Aging Cohort Study (VACS) investigator for nearly 10 years and is presently the principal investigator on four NIH-funded VACS ancillary studies, including three R01 grants. His work also includes international initiatives with the Uganda, Russia, Boston Alcohol Network for Alcohol Research Collaboration on HIV/AIDS (URBAN ARCH) Consortium and as an investigator with the Russia Cohort. He is the principal investigator of a randomized control trial looking at the use of zinc supplementation to reduce alcohol-associated microbial translocation and inflammation, coronary heart disease, and total mortality among ARCH participants in St. Petersburg, Russia.